A physician-initiated double-blind, randomised, placebo-controlled, phase 2 study evaluating the efficacy and safety of inhibition of NADPH oxidase with the first-in-class Nox-1/4 inhibitor, GKT137831, in adults with type 1 diabetes and persistently elevated urinary albumin excretion: Protocol and statistical considerations
Anne T. Reutens, Karin Jandeleit-Dahm, Merlin Thomas, Agus Salim, Alysha M. De Livera, Leon A. Bach, Peter G. Colman, Timothy M.E. Davis, Elif I. Ekinci, Greg Fulcher, Peter Shane Hamblin, Mark A. Kotowicz, Richard J. MacIsaac, Claire Morbey, David Simmons, Georgia Soldatos, Gary Wittert, Ted Wu, Mark E. Cooper, Jonathan E. Shaw
Research output: Contribution to journal › Article › peer-review
35Citations
(Scopus)
Fingerprint
Dive into the research topics of 'A physician-initiated double-blind, randomised, placebo-controlled, phase 2 study evaluating the efficacy and safety of inhibition of NADPH oxidase with the first-in-class Nox-1/4 inhibitor, GKT137831, in adults with type 1 diabetes and persistently elevated urinary albumin excretion: Protocol and statistical considerations'. Together they form a unique fingerprint.